Successful retreatment with glecaprevir/pibrentasvir after sofosbuvir/velpatasvir failure in a patient with hepatitis C-related decompensated cirrhosis complicated by hepatocellular carcinoma - PubMed
5 hours ago
- #Hepatitis C
- #Direct-Acting Antivirals
- #Decompensated Cirrhosis
- A patient with hepatitis C virus (HCV) genotype 1b and decompensated cirrhosis (Child-Pugh class B) complicated by hepatocellular carcinoma (HCC) failed initial sofosbuvir/velpatasvir (SOF/VEL) therapy, with virologic relapse and NS5A resistance substitutions.
- After achieving cancer-free status and stabilization of hepatic function (improved Child-Pugh score), retreatment with glecaprevir/pibrentasvir (GLE/PIB) led to sustained virologic response (SVR), despite limited retreatment options for decompensated cirrhosis post-DAA failure.
- This case suggests that careful retreatment may be feasible in decompensated cirrhosis after DAA failure once liver function stabilizes, highlighting the practical challenges and paramount safety considerations in such complex patients.